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Tolvaptan, an oral vasopressin antagonist, in the treatment of 
hyponatremia in cirrhosis.
Cárdenas A, Ginès P, Marotta P, Czerwiec F, Oyuang J, 
Guevara M, Afdhal N.
J Hepatol 2011 Oct 23 [Epub ahead of print].
Patients with advanced cirrhosis frequently develop 
dilutional hyponatremia due to impairment of their renal 
ability to eliminate solute-free water.
1 Although the patho-
physiology of this disorder is multifactorial, an increased 
hypersecretion of arginine vasopressin (AVP) is a major 
factor.
2 The nonosmotic secretion of AVP in cirrhosis is 
thought to be due to arterial splanchnic vasodilation and 
arterial underfilling, leading to activation of the baroreceptors 
that regulate the release of AVP.
3 The prevalence of hypona-
tremia in cirrhosis, as defined by a serum sodium level of 
135 mmol/L is reported to be 49%, with the prevalence rates 
of serum sodium levels of 130, 125, and 120 mEq/L being 
21.6%, 5.7%, and 1.2%, respectively.
4 In most patients with 
cirrhosis, hyponatremia is usually asymptomatic because it 
develops slowly. However, there are several lines of evidence 
that hyponatremia is a risk factor for the development of 
hepatic encephalopathy, and that it predicts a poor quality of 
life independent of liver function.
5 In addition, hyponatremic 
patients who proceed to liver transplantation appear to have 
an increased risk of neurologic injuries, renal failure, and 
infections in the immediate posttransplant period, and have a 
reduced short-term survival posttransplantation.
6 Hyponatremia 
also predicts short-term mortality in cirrhotic patients awaiting 
liver transplantation, independently of Model for End-stage 
Liver Disease (MELD) score.
7,8 It has thus been proposed 
that serum sodium data should be integrated into the MELD 
scoring system in order to improve its prognostic accuracy.
9
The principle of the management of hypervolemic hypona-
tremia is to induce a negative water balance, with the aim of 
normalizing the increased total body water, which would 
result in an improvement in serum sodium concentration. 
Fluid restriction (1-1.5 L/day) is the most widely accepted 
nonpharmacological therapy, but its efficacy is very limited. 
The administration of hypertonic sodium chloride has been 
common in severe hypervolemic hyponatremia, but its effect 
is only partial and short lived; moreover, additional expansion 
of fluid can worsen ascites and edema. The administration of 
albumin appears to improve serum sodium concentration 
due to an improvement in circulatory function, with suppression 
of the sodium and water-retaining system, including AVP, 
but data supporting its use are limited.
10
The pathophysiologically oriented treatment of hyponatremia 
focuses on inhibiting the actions of AVP. One of the first 
drugs used to treat hypervolemic hyponatremia was demeclocy-
cline, which inhibits the tubular effect of AVP, thereby 
increasing solute-free water clearance; however, its nephrotoxic 
potential has led to its abandonment.
11 In recent years, the 
pharmacological approach to the treatment of hyponatremia 336  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
has made a step forward with the discovery of vaptans, a 
new class of drugs that are able to increase free water 
excretion. They work as antagonists of the V2 receptors of 
vasopressin, which are located in the principal cells of the 
renal collecting duct.
12 Tolvaptan, an orally active, selective 
V2 receptor antagonist, induces the excretion of electrolyte-free 
water without electrolyte excretion.
13 The US Food and 
Drug Administration (FDA) has approved this agent for the 
treatment of hyponatremia associated with syndrome of 
inappropriate antidiuretic hormone (SIADH), cardiac failure, 
and cirrhosis, and the European Medicines Agency has appro-
ved its use for SIADH. These approvals were based on the 
results of several randomized, placebo-controlled, multicenter 
clinical trials,
14-17 one of which－the Study of Ascending 
Levels of Tolvaptan (SALT), published in the New England 
Journal of Medicine in 2006
15－investigated the effects of 
tolvaptan in hyponatremic patients with SIADH, cardiac 
failure, or cirrhosis. The findings of these trials indicated 
that tolvaptan effectively improved serum sodium levels. 
However, the authors did not provide a separate efficacy 
analysis stratified according to the disease associated 
with hyponatremia, and so the actual effects of tolvaptan in 
hyponatremic patients with cirrhosis could not be ascertained 
from that study. Given that tolvaptan is the only oral vaptan 
approved for the management of hyponatremia, its efficacy 
in the population of patients with cirrhosis is of interest to 
practicing clinicians. Therefore, we provide herein the results 
of a subgroup analysis of the SALT trials, e-published in the 
Journal of Hepatology, evaluating the efficacy and safety of 
tolvaptan in hyponatremic patients with liver cirrhosis.
18
The study of Cárdenas et al (reported in this issue) examined 
cirrhotic patients with hyponatremia who received 15 mg of 
oral tolvaptan (n=63; increased to 30 or 60 mg if needed) or 
placebo (n=57) once daily for 30 days. Primary endpoints 
were changes in serum sodium concentration at 4 and 30 days 
of therapy. Tolvaptan was found to be associated with a 
marked and significant increase in serum sodium concentration 
compared to placebo at day 4 (absolute average increases of 
4.7 vs. 0.3 mmol/L, respectively) and at day 30 (4.2 vs. 1.3 mmol/L, 
respectively). The proportion of patients on tolvaptan whose 
serum sodium normalized (i.e., >135 mmol/L ) at day 4 was 
41%, as compared to 11% for placebo; at day 30 these 
proportions were 33% and 19%, respectively. Although 
more than a half of patients in the tolvaptan group did not 
achieve normalization, with the proportions still being >3- to 
1.5-fold greater than for the placebo group. The serum 
sodium levels had returned to pretreatment values at 1 week 
after stopping treatment. Interestingly, the administration of 
tolvaptan was associated with a significant improvement in 
the scores of the mental component of the medical outcomes 
study 12-item short-form general health survey. This suggests 
that correcting hyponatremia improves the quality of life in 
patient with liver cirrhosis.
Another clinically relevant finding was that combining 
tolvaptan with diuretics did not lead to renal insufficiency. 
However, other clinical outcomes such as ascites resolution 
and changes in the degree of hepatic encephalopathy were 
not assessed. Tolvaptan was found to be safe, with no 
significant differences in adverse events compared to the 
placebo group. Side effects that were more frequent in the 
tolvaptan group were dry mouth and thirst. An infrequent, 
yet important adverse event was gastrointestinal bleeding, 
whose incidence was higher in the tolvaptan group than in 
the placebo group (9.5% vs. 1.8%, respectively). The underlying 
source of the bleeding was probably esophageal varices, but 
this was unclear in the event descriptions. The increased risk 
of bleeding was discussed during the FDA review of 
tolvaptan, which led to it being attributed to the effect of 
tolvaptan on vitamin-K-dependent clotting factors and 
platelet function.
13,19
In conclusion, oral tolvaptan for 1  month significantly 
improved the serum sodium levels and health-related quality 
of life in hyponatremic patients with liver cirrhosis. 
Tolvaptan did not lead to renal insufficiency, even when the 
drug was given with diuretics. Although the side effects 
were comparable to those observed in placebo-treated 
patients, tolvaptan was associated with a higher incidence of 
gastrointestinal bleeding. These findings indicate that 
further study is warranted into the use of tolvaptan in order 
to evaluate its long-term risks and benefits in hyponatremic 
patients with cirrhosis.
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